Dongzhimen Hospital, Beijing University of Chinese Medicine.
Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, P.R. China.
Medicine (Baltimore). 2021 Jan 8;100(1):e23966. doi: 10.1097/MD.0000000000023966.
Ulcerative colitis (UC) belongs to chronic colitis whose etiology and pathogenesis still have remained unclear. Hyperbaric oxygen therapy (HBOT) has been demonstrated to be effective for UC therapy. Still, evidence of its efficacy and safety is inconclusive. The purpose of the protocol is to evaluate the efficacy and safety of HBOT in UC therapy.
This systematic review will retrieve studies that meet the requirements in Embase, MEDLINE, PubMed, Web of Science, Cochrane Library Central Register of Controlled Trials, the Chinese Biomedical Literature Database (CBM), China national knowledge infrastructure database (CNKI), Wei Pu database, Wan fang database, SinoMed, Google scholar, and Baidu Scholar from their inception to November 2020. Two authors are to be independent in their article selection, data collection, and research quality assessments. The primary outcome is the clinical effectiveness. And the secondary outcomes will include 4 criteria. RevMan 5.3 software will be utilized for analysis of the data.
The results of this study are to be submitted via a peer-reviewed journal.
The study is to assess the effectiveness and safety of HBOT for UC and provide valid and reliable evidence regarding HBOT for UC.
INPLASY2020100118.
溃疡性结肠炎（UC）属于慢性结肠炎，其病因和发病机制仍不清楚。高压氧治疗（HBOT）已被证明对 UC 的治疗有效。然而，其疗效和安全性的证据尚无定论。本方案的目的是评估 HBOT 在 UC 治疗中的疗效和安全性。
本系统评价将检索符合 Embase、MEDLINE、PubMed、Web of Science、Cochrane 图书馆对照试验中心注册、中国生物医学文献数据库（CBM）、中国知网数据库（CNKI）、维普数据库、万方数据库、SinoMed、谷歌学术和百度学术从成立到 2020 年 11 月的要求的研究。两位作者将独立进行文章选择、数据收集和研究质量评估。主要结局是临床疗效。次要结局将包括 4 个标准。RevMan 5.3 软件将用于分析数据。
本研究的结果将提交给同行评议的期刊。
本研究旨在评估 HBOT 治疗 UC 的有效性和安全性，并为 HBOT 治疗 UC 提供有效和可靠的证据。
INPLASY 注册号：INPLASY2020100118。
